T. Rowe Price Associates
TARA icon

T. Rowe Price Associates’s Protara Therapeutics TARA Stock Holding History

T. Rowe Price Associates’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$148K Buy
38,483
+2,177
+6% +$10.4K ﹤0.01% 3084
2026
Q1 		$190K Buy
36,306
+15,570
+75% +$92.2K ﹤0.01% 2859
2025
Q4 		$111K Buy
20,736
+4,383
+27% +$24.4K ﹤0.01% 2932
2025
Q3 		$72K Hold
16,353
– – ﹤0.01% 2976
2025
Q2 		$50K Buy
+16,353
New +$56.4K ﹤0.01% 3008
2021
Q2 		– Sell
-319,326
Closed -$5.03M – 2953
2021
Q1 		$5.03M Sell
319,326
-114,272
-26% -$2.12M ﹤0.01% 1466
2020
Q4 		$10.5M Sell
433,598
-14,495
-3% -$312K ﹤0.01% 1343
2020
Q3 		$7.54M Buy
+448,093
New +$10.4M ﹤0.01% 1354

Other funds holding TARA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

T. Rowe Price Associates's TARA Position: Q2 2026 in Review

T. Rowe Price Associates increased its Protara Therapeutics (TARA) stake by 6% in Q2 2026, buying an estimated $10.4K and bringing the position to 38,483 shares worth $148K. The position accounts for ﹤0.01% of the portfolio, ranked #3084.

T. Rowe Price Associates first reported a position in TARA in Q3 2020 and has held it in 8 quarters since. The position peaked at $10.5M in Q4 2020. 119 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • T. Rowe Price Associates held 38,483 shares of Protara Therapeutics worth $148K as of Q2 2026.
  • T. Rowe Price Associates bought 2,177 Protara Therapeutics shares in Q2 2026, an estimated $10.4K.
  • Protara Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #3084 holding.
  • T. Rowe Price Associates first reported a position in Protara Therapeutics in Q3 2020 and has held it in 8 quarters since.
  • T. Rowe Price Associates's Protara Therapeutics position peaked at $10.5M in Q4 2020.
  • 119 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.